Genmab — Februar 2013
-
316K
-
-
det er merill lynch, credit suisse på den ene side og ens og ddb på den anden side. Jeg tror det må være ATP der losser ud
-
Vedr. Solsens link. Så kan Ofa måske profitere af Ibrutinib. In combination with ofatumumab (Arzerra) on patients with chronic lymphocytic leukemia / small lymphocytic leukemia / prolymphocytic leukemia1 (CLL/SLL/ PLL1) and Richter transformation, results demonstrate that the combination was well-tolerated and highly active in patients with heavily pretreated relapsed/refractory CLL/SLL. The drug is described to have a rapid onset of response, low relapse rate, and favorable safety profile.http
-
-
In this ongoing trial patients with relapsed/refractory CLL/SLL who have received two or more prior therapies are treated with ibrutinib (420 mg) daily until disease progression, followed by concomitant ofatumumab with continued ibrutinib until progression.
For the CLL/SLL/PLL patients the overall response rate, as measured by IWCLL criteria and progression-free survival is 100%, with a median follow-up of 9.8 months
-
Så de laver head to head med ofa i den indikation den er godkendt i. Det er svært at se fordelen i for Genmab.
-
Ibrutinib bliver en stor spiller og også her har Janssen været vågne og villige til at betale for en god aftale. Lad os håbe at Daratumumab bliver en lige så stor succes - og ikke helt uvæsentligt, at Janssen sidder på både Ibrutinib og Daratumumab. Hvem ved det kan blive fremtidens killer-kombi uden kemo !
-
-
Det er altså meget spændende at de gør dette med ibrutinib
-
Især når man så tænker på at man har ændret protokol i phase I/II studiet efter Janssen kom ombord....
-
måske man skulle købe lidt J&J aktier til pensionen
-
den er ikke voldsom dyr
-
Det ville give et kæmpe boost til genmabs markedsværdi at dara NDA kan indsendes når phase I/II studiet er færdigt
-
ja det vil helt sikkert gøre casen helt anderledes i og med at man så vil få en "rituxian agtig" status i MM.
-
men man tør jo næsten ikke tro på det
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind